Treatment with brentuximab vedotin plus bendamustine in unselected patients with CD30‐positive aggressive lymphomas-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Treatment with brentuximab vedotin plus bendamustine in unselected patients with CD30‐positive aggressive lymphomas

Published:2020-01-10 Issue:3 Volume:104 Page:251-258
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:Eur J Haematol

Author:

Wagner Sandro M.¹²^ORCID,Melchardt Thomas¹²,Egle Alexander¹²³,Magnes Teresa¹²,Skrabs Cathrin⁴,Staber Philipp⁴,Simonitsch‐Klupp Ingrid⁵,Panny Michael⁶,Lehner Barbara⁶,Greil Richard¹²³,Keil Felix⁶^ORCID,Jäger Ulrich⁴,Sillaber Christian⁴

Affiliation:

1. 3rd Medical Department with Hematology and Medical Oncology Paracelsus Medical University Salzburg Salzburg Austria

2. Salzburg Cancer Research Institute‐CCCIT Salzburg Austria

3. Cancer Cluster Salzburg Salzburg Austria

4. Division of Hematology and Hemostaseology Department of Medicine I Medical University of Vienna Vienna Austria

5. Clinical Institute of Pathology Medical University of Vienna Vienna Austria

6. Third Medical Department for Hematology and Oncology Hanusch Krankenhaus Wien Vienna Austria

Publisher

Wiley

Subject

Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ejh.13368

Reference19 articles.

1. Sequential immunotherapy in a patient with primary refractory Hodgkin lymphoma and novel mutations

2. Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma

3. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model

4. VIP (etoposide, ifosfamide and cisplatinum) as a salvage intensification program in relapsed or refractory Hodgkin’s disease

5. ESHAP as salvage therapy for relapsed or refractory Hodgkin’s lymphoma

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Complete hematologic response in a patient with multiple pretreated angioimmunoblastic T‐cell lymphoma after belinostat therapy followed by allogeneic stem cell transplantation: A case report;Clinical Case Reports;2024-07

2. Novel clinical risk stratification and treatment strategies in relapsed/refractory peripheral T-cell lymphoma;Journal of Hematology & Oncology;2024-06-01

3. Salvage therapy with brentuximab-vedotin and bendamustine for patients with R/R PTCL: a retrospective study from the LYSA;Blood Advances;2022-12-07

4. CD30+ Lymphoproliferative Disorders as Potential Candidates for CD30-Targeted Therapies;Archives of Pathology & Laboratory Medicine;2022-03-17

5. Use of ifosfamide, carboplatin and etoposide in combination with brentuximab vedotin or romidepsin based on CD30 positivity in relapsed/refractory peripheral T‐cell lymphoma;Cancer Reports;2022-03-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3